

Publications:
Debra Simmons, MD, MS, FACE, FACP
Division of Endocrinology, Metabolism & Diabetes
Department of Internal Medicine, University of Utah

2019

- [Ghazi L, Pajewski NM, Rifkin DE, Bates JT, Chang TI, Cushman WC, Glasser SP, Haley WE, Johnson KC, Kostis WJ, Papademetriou V, Rahman M, Simmons DL, Taylor A, Whelton PK, Wright JT, Bhatt UY, Drawz PE \(2019\). Effect of Intensive and Standard Clinic-Based Hypertension Management on the Concordance Between Clinic and Ambulatory Blood Pressure and Blood Pressure Variability in SPRINT. *J Am Heart Assoc*, 8\(14\).](#)
- [Nowak KL, Chonchol M, Jovanovich A, You Z, Bates J, Foy C, Glasser S, Killeen AA, Kostis J, Rodriguez CJ, Segal M, Simmons DL, Taylor A, Lovato LC, Ambrosius WT, Supiano MA \(2019\). Serum Sodium and Pulse Pressure in SPRINT. *Am J Hypertens*, 32\(7\), 649-656.](#)
- [Alweis RL, Williams CM, Luther VP, Simmons DL, Kopelman R, Angus SV, Liao S, Nagalla S, Muchmore EA \(2019\). AAIM Guidelines for Interview and Post-Interview Communication for Graduate Medical Education Recruitment. *American journal of medicine*.](#)
- [Collichio F, Vassallo P, Jeremiah J, Forman L, Dubois L, Simmons D, Chretien K, Amin A, Coleman D \(March 2019\). Parental Leave in Graduate Medical Education: Recommendations for Reform. *Am J Med*, 132\(3\), 385-389.](#)

2018

- [Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE \(2018\). Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. *Clin J Am Soc Nephrol*, 13\(11\), 1693-1702.](#)

2017

- [Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J \(2017, Aug. 24\). Impact of Intensive Blood Pressure Therapy on Patient-Reported Outcomes. *N Engl J Med*, 377\(8\), 733-744.](#)
- [Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL,](#)

[Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V, SPRINT Research Group \(2017, Aug\). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. *Diabetes Care*, 40\(10\), 1401-1408.](#)

- [Lyubarova R, Robinson JG, Miller M, Simmons DL, Xu P, Abramson BL, Elam MB, Brown TM, McBride R, Fleg JL, Desvigne-Nickens P, Ayenew W, Boden WE, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes AIM-HIGH Investigators \(2017 Sep - Oct\). Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. *Clin Lipidol*, 11\(5\), 1201-1211.](#)
- [Ravindra VM, Raheja A, Corn H, Driscoll M, Welt C, Simmons DL, Couldwell WT \(2017\). Primary pituitary diffuse large B-cell lymphoma with somatotroph hyperplasia and acromegaly: case report. *J Neurosurg*, 126\(5\), 1725-1730.](#)

2016

- [Eli IM, Raheja A, Corn HJ, Simmons DL, Palmer CA, Couldwell WT \(2016 Nov\). Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma. *World Neurosurg*. *World Neurosurg*, 95, 622.](#)
- [Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE \(2016\). Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. *Am J Med*, 129\(7\), 753.e13-22.](#)
- [Asleh R, Levy NS, Doros G, Costacou T, Robinson JG, Blum S, Goldenstein H, Boden WE, Simmons DL, Lacy MA, Grunberger G, Anderson TJ, Levy AP \(2016\). Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. \[Letter to the editor\]. *J Am Coll Cardiol*, 67\(21\), 2553-4.](#)

2015

- [Schwartz AV, Chen H, Ambrosius WT, Sood A, Josse RG, Bonds DE, Schnall AM, Vittinghoff E, Bauer DC, Banerji MA, Cohen RM, Hamilton BP, Isakova T, Sellmeyer DE, Simmons DL, Shibli-Rahhal A, Williamson JD, Margolis KL \(2015\). Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study. *J Clin Endocrinol Metab*, 100\(11\), 4059-66.](#)

2014

- [Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkinson HH, Hamilton BP, Josse RG, O'Connor PJ, Simmons DL, Tiktin M, Schwartz AV \(2014\). Intensive blood pressure](#)

[control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. / *Gen Intern Med*, 29\(12\), 1599-606.](#)

- [Margolis KL, Palermo L, Vittinghoff E, Evans GW, Atkins HH, Hamilton BP, Josse RG, OConnor PJ, Simmons DL, Tiktin M, Schwartz AV \(08/16/2014\). Intensive Blood Pressure Control, Falls, and Fractures in Patients with Type 2 Diabetes: The ACCORD Trial. / *Gen Intern Med*, Dec:29\(12\), 1599-606.](#)
- [Punthakee Z, Miller ME, Simmons DL, Riddle MC, Ismail-Beigi F, Brillon DJ, ergenstal RM, Savage PJ, Hramiak I, Largay JF, Sood A, Gerstein HC \(July 2014\). Durable change in glycaemic control following intensive type 2 diabetes management in the ACCORD Clinical Trial. *Diabetologia*, Oct\(10\), 2030-7.](#)
- [Linz PE, Lovato LC, Byington RP, OConnor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB \(2014\). Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. *Diabetes Care*, 37\(3\), 686-93.](#)

2013

- Agarwal M, Kantorovich V, Simmons DL (2013). Diabetes Mellitus. In Means K, Kortebein K, Buschbacher R, Eds. (Eds.), *Geriatrics: Rehabilitation Medicine Quick Reference Series* (pp. 80-83). New York: Desmos Medical Publishing.